We discuss the results of a Phase II clinical trail studying the efficacy of high dose aflibercept (8mg) for treating neovascular AMD with Dr. David Brown of Retina Consultants of Texas in Houston.

We discuss the results of a Phase II clinical trail studying the efficacy of high dose aflibercept (8mg) for treating neovascular AMD with Dr. David Brown of Retina Consultants of Texas in Houston.

High Dose (8mg) Aflibercept for Treatment of Neovascular AMD

We discuss new developments in the diagnosis and therapy of choroidal melanoma with Dr. Paul Finger, Clinical Professor, NYU and Chair, Eye Cancer Foundation.

We discuss new developments in the diagnosis and therapy of choroidal melanoma with Dr. Paul Finger, Clinical Professor, NYU and Chair, Eye Cancer Foundation.

New Developments in the Management of Choroidal Melanoma

We discuss the two year results of a Phase I/II trial of a stem cell  implant for the treatment of geographic atrophy with Dr. Amir Kashani, Associate Professor, Wilmer Eye Institute.

We discuss the two year results of a Phase I/II trial of a stem cell  implant for the treatment of geographic atrophy with Dr. Amir Kashani, Associate Professor, Wilmer Eye Institute.

A Stem Cell Implant for the Treatment of Geographic Atrophy

We discuss the one year results of the DERBY and OAKs studies treating geographic atrophy with Dr. David Lally,  Assistant Professor University of Massachusetts and Tufts University.

We discuss the one year results of the DERBY and OAKs studies treating geographic atrophy with Dr. David Lally,  Assistant Professor University of Massachusetts and Tufts University.

DERBY and OAKS Results

We discuss the use of deep learning techniques in the detection and management of macular degeneration with Dr. Pearse Keane, Consultant Moorfields Eye Hospital, Professor of Artificial Medical Intelligence University College London.

We discuss the use of deep learning techniques in the detection and management of macular degeneration with Dr. Pearse Keane, Consultant Moorfields Eye Hospital, Professor of Artificial Medical Intelligence University College London.

Artificial Intelligence in the Management of Macular Degeneration

In our latest update, We discuss the use of APX3330 a novel oral agent for the treatment of diabetic retinopathy with Dr. David Boyer, Retina Vitreous Associates, Adjunct Professor USC Roski Eye Institute.

In our latest update, We discuss the use of APX3330 a novel oral agent for the treatment of diabetic retinopathy with Dr. David Boyer, Retina Vitreous Associates, Adjunct Professor USC Roski Eye Institute.

An Oral Agent for the Treatment of Diabetic Retinopathy

We discuss the use of a home based OCT system with artificial intelligence to monitor the treatment of neovascular AMD with Dr. Nancy Holekamp, Professor of Clinical Ophthalmology, Washington University School of Medicine.

We discuss the use of a home based OCT system with artificial intelligence to monitor the treatment of neovascular AMD with Dr. Nancy Holekamp, Professor of Clinical Ophthalmology, Washington University School of Medicine.

Home OCT Monitoring of Neovascular AMD Treatment

We discuss the two year results of the first bispecific agent for the treatment of diabetic macular edema with Dr. John Wells III, from Palmetto Retina Clinic.

We discuss the two year results of the first bispecific agent for the treatment of diabetic macular edema with Dr. John Wells III, from Palmetto Retina Clinic.

Faricimab in Diabetic Macular Edema: 2 Year Results of the RHINE and YOSEMITE studies

We discuss the results of the Kingfisher trail, a study employing broluizumab q4 weeks for the treatment of diabetic macular edema with Dr. Mark Barakat, Assistant Clinical Profess of Ophthalmology, University of Arizona College of Medicine Phoenix.

We discuss the results of the Kingfisher trail, a study employing broluizumab q4 weeks for the treatment of diabetic macular edema with Dr. Mark Barakat, Assistant Clinical Profess of Ophthalmology, University of Arizona College of Medicine Phoenix.

The Kingfisher Trial of Brolucizumab for DME

We examine the role of sub retinal fluid in the treatment of neovascular AMD with Dr. David Sarraf, Professor of Ophthalmology, UCLA Stein Eye Institute.

We examine the role of sub retinal fluid in the treatment of neovascular AMD with Dr. David Sarraf, Professor of Ophthalmology, UCLA Stein Eye Institute.

Subretinal Fluid in Neovascular AMD: Friend or Foe?

Retina Synthesis is a data-focused resource exploring therapies in development for retinal diseases.

We discussed and learned with Samarendra Mohanty, PhD: President and Founder of Nanoscope Technologies, about the fascinating science of vision restoration through making bipolar cells light-sensitive and the development program of the intravitreally administered gene therapy vMCO-010c, currently being investigated in a Ph2b trial of patients with retinitis pigmentosa.

We discussed and learned with Samarendra Mohanty, PhD: President and Founder of Nanoscope Technologies, about the fascinating science of vision restoration through making bipolar cells light-sensitive and the development program of the intravitreally administered gene therapy vMCO-010c, currently being investigated in a Ph2b trial of patients with retinitis pigmentosa.

Optogenetics

We discuss a phase I study examining the effect of plasma kvllikrein inhibition on diabetic macular edema with Dr. Arshad Khanani, Sierra Eye Associates, University of Nevada Reno.

We discuss a phase I study examining the effect of plasma kvllikrein inhibition on diabetic macular edema with Dr. Arshad Khanani, Sierra Eye Associates, University of Nevada Reno.

Inhibition of Plasma Kallikrein in Diabetic Macular Edema

Join these renowned experts for a panel discussion on how to incorporate into clinical practice the latest treatments for neovascular age-related macular degeneration (nAMD). The panelists will also share the latest outcomes data and their clinical experience using these therapies.

Join these renowned experts for a panel discussion on how to incorporate into clinical practice the latest treatments for neovascular age-related macular degeneration (nAMD). The panelists will also share the latest outcomes data and their clinical experience using these therapies.

Neovascular AMD: Unpacking Surgical Disease Management Options

We review the current status of the Ocular Therapeutics TKI sustained release delivery system for treatment of neovascular AMD with Dr. Andrew Moshfeghi, Associate Professor of Ophthalmology USC Roski Eye Institute.

We review the current status of the Ocular Therapeutics TKI sustained release delivery system for treatment of neovascular AMD with Dr. Andrew Moshfeghi, Associate Professor of Ophthalmology USC Roski Eye Institute.

Ocular Therapeutics Sustained Release TKI Trial

Allen Ho

We review current status of clinical research on gene therapy for neovascular AMD and diabetic retinopathy with Dr. Allen Ho, Professor of Ophthalmology, Jefferson Medical College and Wills Eye Hospital.

We review current status of clinical research on gene therapy for neovascular AMD and diabetic retinopathy with Dr. Allen Ho, Professor of Ophthalmology, Jefferson Medical College and Wills Eye Hospital.

Gene Therapy of nAMD and Diabetic Retinopathy with Dr. Allen Ho

We review long term results of the Port Delivery System for treating neovascular AMD  with Dr. David Eichenbaum of Retina Vitreous Associates of Florida, Collaborative Associate Professor University of South Florida.

We review long term results of the Port Delivery System for treating neovascular AMD  with Dr. David Eichenbaum of Retina Vitreous Associates of Florida, Collaborative Associate Professor University of South Florida.

Long Term Results of the Port Delivery System

We review the results of the phase I Graybug study Altissimo using sustained release tyrosinase kinase inhibitor for long term treatment of neovascular AMD with Dr. Veeral Sheth, Chicago, Illinois, Assistant Clinical Professor University of Illinois at Chicago.

We review the results of the phase I Graybug study Altissimo using sustained release tyrosinase kinase inhibitor for long term treatment of neovascular AMD with Dr. Veeral Sheth, Chicago, Illinois, Assistant Clinical Professor University of Illinois at Chicago.

The Altissimo Study using a TKI for nAMD

The fluocinolone implant at 3 years is a useful modality for treating diabetic macular edema. Discussion with Dr. Michael Singer, Adjunct Professor University of Texas at San Antonio.

The fluocinolone implant at 3 years is a useful modality for treating diabetic macular edema. Discussion with Dr. Michael Singer, Adjunct Professor University of Texas at San Antonio.

The Paladin Study of the Fluocinolone Implant Treating Diabetic Macular Edema

We discuss the DAVIO trial of EYP-1901 with Dr. Jay S. Duker, Chief Operating Officer of Eyepoint Pharmaceuticals.

We discuss the DAVIO trial of EYP-1901 with Dr. Jay S. Duker, Chief Operating Officer of Eyepoint Pharmaceuticals.

A Tyrosine Kinase Inhibitor that Successfully Treats nAMD

We review the results of the KS-301 wet macular degeneration trial with Dr. Carl Regillo,Chief of the Retina Service at Wills Eye Hospital

We review the results of the KS-301 wet macular degeneration trial with Dr. Carl Regillo, Chief of the Retina Service at Wills Eye Hospital

Late Breaking News on Kodiak Dazzle Trial

Retina Synthesis

The best podcast episodes on physical health. Episodes talk about your diet, sleep, exercise and all the things that people do to improve their physical health and live a healthier life. This topic is for everyone, with applications in all of our everyday lives. Add episodes you're interested into your queue below!

Best Episodes on Physical Health & Your Body

The best podcast episodes on Startups. For anyone working in a startup, or anyone interested in the incredible stories behind how people built companies like Instagram, and Facebook. Offering both practical advice and insights, as well as the stories for how many of the biggest startups got to where they are today. Add episodes you're interested into your queue below!